Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal enoxaparin prophylaxis to block SARS-CoV-2 nasal epithelial binding
NL-OMON50776Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of enoxaparin in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Amsterdam University Medical Center. Started Jan 2021; status: active, not recruiting.
02
Drugs
enoxaparin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON50776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50776.